IGI Logo

Aurobindo Pharma is currently trading at Rs. 542.05, up by 8.75 points or 1.64% from its previous closing of Rs. 533.30 on the BSE.

The scrip opened at Rs. 531.45 and has touched a high and low of Rs. 543.45 and Rs. 530.00 respectively. So far 32014 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1003.85 on 06-Jul-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 544.90 and Rs. 506.70 respectively. The current market cap of the company is Rs. 31754.94 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.30% and 9.86% respectively.

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Triamcinolone Acetonide Injectable Suspension 200 mg/5 mL & 400 mg/10 mL. Triamcinolone Acetonide Injectable Suspension USP, 200 mg/5 mL (40 mg/mL) Multiple-dose vials and 400 mg/10 mL (40 mg/mL) Multiple-dose vials, to be bioequivalent and therapeutically equivalent to the RLD, Kenalog-40 Injectable Suspension, 40 mg/mL, of Bristol-Myers Squibb Company. The product is being launched this month.

The approved product has an estimated market size of around $73 million for the twelve months ending May 2022, according to IQVIA. Triamcinolone Acetonide Injectable Suspension is in therapeutic Category of Synthetic glucocorticoid corticosteroid and indicated for the treatment of Intramuscular and Intra-Articular.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.